Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Nov 15;54(22):5788-92.

Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies

Affiliations
  • PMID: 7954400

Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies

D R Hipfner et al. Cancer Res. .

Abstract

MRP is a M(r) 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines and has been shown to cause multidrug resistance in transfected cells. Five murine hybridoma cell lines (QCRL-1, QCRL-2, QCRL-3, QCRL-4, and QCRL-6) have been generated which secrete monoclonal antibodies (MAbs) that react specifically with membrane proteins of MRP-overexpressing, multidrug-resistant, drug-selected H69AR cells and MRP-transfected HeLa cells (T5) but not the respective parental (H69) and vector-transfected (C1) cells. The ability of three of these MAbs (QCRL-1, QCRL-2, and QCRL-3) to selectively immunoprecipitate a M(r) 190,000 protein from 35S-labeled H69AR and T5 membranes indicates that these MAbs are specific for MRP. MAb QCRL-1 is also capable of detecting the low levels of MRP present in revertant H69PR cells by immunoblot analysis. Indirect immunofluorescence analyses show that MAbs QCRL-1, QCRL-2, and QCRL-3) strongly and differentially react with fixed T5 and H69AR cells but not with unfixed cells, suggesting that these MAbs recognize intracellular MRP epitopes. The availability of reagents for the specific and sensitive immunodetection of MRP should greatly facilitate biological and clinical studies of this novel drug resistance protein.

PubMed Disclaimer

Publication types

Substances

LinkOut - more resources